🇺🇸 FDA
Pipeline program

Ivonescimab 10 mg/kg

GORTEC 2024-04

Phase 3 small_molecule active

Quick answer

Ivonescimab 10 mg/kg for Squamous Cell Carcinoma Head and Neck Cancer (HNSCC) is a Phase 3 program (small_molecule) at Summit Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Summit Therapeutics
Indication
Squamous Cell Carcinoma Head and Neck Cancer (HNSCC)
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials